ADVI Analysis: MedPAC Meeting April 2023

Pharmaceuticals and Biotech Federal And State Policy Pharmaceuticals and Biotech

April 17, 2023

The Medicare Payment Advisory Commission (MedPAC) held its latest meeting on April 13-14, 2023 (link). The following relevant topics were discussed: Addressing the high prices of drugs covered under Medicare Part B Aligning fee-for-service payment rates across ambulatory settings; Mandated report: Evaluation of a prototype design for a post-acute care prospective payment system; Assessing post-sale rebates for prescription drugs in Medicare Part D; Assessing the need for Medicare safety net payments for skilled nursing facilities and home health agencies; and Mandated report: Telehealth in Medicare. Read the ADVI Angle on key takeaways.

The Medicare Payment Advisory Commission (MedPAC) held its latest meeting on April 13-14, 2023 (link). The following relevant topics were discussed. 
  • Addressing the high prices of drugs covered under Medicare Part B 
  • Aligning fee-for-service payment rates across ambulatory settings 
  • Mandated report: Evaluation of a prototype design for a post-acute care prospective payment system 
  • Assessing postsale rebates for prescription drugs in Medicare Part D
  • Assessing the need for Medicare safety net payments for skilled nursing facilities and home health agencies 
  • Mandated report: Telehealth in Medicare 

ADVI Angle

The following are key takeaways from the April meeting:

  • Addressing the high prices of drugs covered under Medicare Part B
    • MedPAC staff reviewed the package of Part B policies and draft recommendations to address (1) high prices and uncertain clinical evidence for Part B accelerated approval drugs, (2) lack of price competition for drugs with similar health effects, and (3) financial incentives associated with the percentage add-on to Medicare Part B’s payment rate. 
    • Commissioners voted unanimously yes on all three draft recommendations. This will be included in the June 2023 report.
  • Aligning fee-for-service payment rates across ambulatory settings 
    • MedPAC staff presented the issue of payment rate variation for ambulatory services in different settings and how it increases Medicare spending. Some services can be safely provided in multiple settings, and payment rates should be aligned to match the lowest cost setting without affecting access to care. The recommendation is to align payment rates for select services across the three ambulatory settings, and the commissioners will review and vote on it.
    • All Commissioners voted in support of the draft recommendation.
  • Mandated report: Evaluation of a prototype design for a post-acute care prospective system 
    • MedPAC staff presented the Congress required that the Commission and the Secretary of HHS to develop prototypes for a unified PAC payment system that set payments based on characteristics rather than setting for all PAC providers. Commissioners have reviewed findings showing a PAC PPS is feasible, and considered the policies that should accompany it.
    • All Commissioners voted in support of the draft recommendation.
  • Assessing post sale rebates for prescription drugs in Medicare Part D
    • MedPAC staff reviewed and discussed findings from an ongoing analysis of the “Direct or Indirect Renumeration” DIR data. These findings will serve as a baseline for comparison as the Inflation Reduction Act (IRA) mandated challenges are implemented. 
    • A draft recommendation was not presented in this session.
  • Assessing the need for Medicare safety net payments for skilled nursing facilities and home health agencies 
    • MedPAC staff reviewed the Commission’s approach to identify and support safety-net providers that serve low-income Medicare beneficiaries. This continues the application of the safety net framework that was applied in the June 2022 Report to Congress.  
    • A draft recommendation was not presented in this session. 
  • Mandated report: Telehealth in Medicare
    • MedPAC staff presented the expansion of Medicare’s coverage of telehealth services during the COVID-19 pandemic and the requirement for the Commission to submit a report on the impact of this expansion on access, quality, and payment policy by June 2023. The Commission previously presented a policy option for the Congress and CMS to temporarily continue some of the telehealth expansions to gather more evidence of their impact. The Commission has continued to assess the use of telehealth services during the pandemic and discuss alternative approaches for payment.

This is an abridged and delayed release. Full ADVI Analysis content is distributed in real time for retainer clients. Get in touch to learn more about how we can support your commercialization, market access, and policy needs.


CEO insights

Real analysis from people who’ve been there

Cell and Gene Precision Medicine State Policy

The 2026 Rare Disease Reality

Orphan drugs now represent approximately 20 percent of total prescription spend, and over 52 percent of the cell and gene …

Marc Samuels, JD, MPH
February 26, 2026

AI in the Patient Care Paradigm: Examining Regulatory Challenges to Clinical Adoption  

Artificial intelligence could transform clinical care, but regulatory hurdles slow adoption. Ensuring healthcare AI has adequate policy safeguards is paramount …

Marc Samuels, JD, MPH
December 30, 2025

Precision Medicine

2026 Life Sciences Forecast: AI, Next-Gen Cell & Gene Therapy, and Policy Disruption

In 2026, we expect the healthcare landscape to be defined by technology breakthroughs, market access disruption, and profound policy changes. …

Marc Samuels, JD, MPH
December 16, 2025

Cell and Gene

Delivering on CAR T-cell Therapy’s Promise: Policy Solutions for the Next Era of Cancer Care

CAR T-cell therapy offers a groundbreaking treatment option for patients with relapsed or refractory hematologic malignancies, yet access remains severely …

Alicia Silver, MPP
November 21, 2025

Inflation Reduction Act Pharmaceuticals and Biotech

Why is Medicare Data Central to IRA Negotiations?

The Inflation Reduction Act (IRA), passed in 2022, has transformed the way drug pricing will be managed in the United …

September 10, 2025

Rare Disease

The Unintended Consequences of Drug Pricing Policies on Orphan Drug Development

Rare diseases impact nearly 1 in 10 people in the US and are largely untreated, with 95 percent lacking FDA-approved …

June 23, 2025

State Policy

ADVI Analysis: HRSA 340B Covered Entity Audits

Analysis of HRSA 340B Covered Entity Audits Since the 340B Drug Pricing Program began in 1992, covered entities’ participation has …

March 10, 2025

ADVI Angle Vertical

Rare Disease State Policy

Prescription Drug Affordability Boards: Access Concerns and Implications for Rare Diseases and Conditions

In recent years, states have increasingly enacted Prescription Drug Affordability Boards (PDABs). While their stated purpose is to increase affordability, …

February 28, 2025

Reach out

Own your edge

We don’t just guide the market. We shape it. Map your market access moves with #ADVIIntelligence. Proven advantage. Unmatched partnership.